▾Tenoxicam - yet another NSAID

1989 ◽  
Vol 27 (19) ◽  
pp. 73-74
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trials ◽  
Adverse Effects ◽  
Inflammatory Drug ◽  
Relative Safety ◽  
Anti Inflammatory

Tenoxicam (Mobiflex) is a new non-steroidal anti-inflammatory drug (NSAID) being promoted by two major companies, Roche and Glaxo (Duncan Flockhart), which have hitherto had no products in this field. It is licensed for “the relief of pain and inflammation in osteoarthritis and rheumatoid arthritis”. We have previously highlighted the balance between efficacy and risk of serious adverse effects for NSAIDs;1 the relative safety of a new NSAID is particularly difficult to quantify because of the few patients studied in clinical trials. Does tenoxicam offer any features that justify introduction of yet another NSAID?

Helenalin: An Anti-Inflammatory and Anti-Neoplastic Agent: A Review

2020 ◽  
Vol 16 (8) ◽  
pp. 1134-1146
Author(s):  
Priyanka Kriplani ◽  
Kumar Guarve ◽  
Uttam S. Baghel
Keyword(s):  
Rheumatoid Arthritis ◽  
Adverse Effects ◽  
Chronic Conditions ◽  
Review Article ◽  
Google Scholar ◽  
Medical Community ◽  
Inflammatory Agent ◽  
Skin Cancers ◽  
Medicinal Properties ◽  
Anti Inflammatory

Objective: Helenalin is a natural anti-inflammatory agent that is proving its efficacy to treat various medical conditions. Though many plants are proving their effectiveness but their mechanisms are still not well understood. The objective of the review is to summarize various mechanisms of helenalin to treat inflammatory disorders and cancers, adverse effects, and avenues of further research. Methods: Structured research was carried out including Pub med, Science direct Medline, Research Gate and Google Scholar to find all articles published on helenalin. Various keywords used were “helenalin”, “Arnica”, “cancer”, “anti-inflammatory”, “cardiovascular”, “IBD”, “pharmacokinetics” etc. The aim of the review was to find out the problem prevailing in the data published to date which will help the researchers to investigate the molecule clinically. Results: Seventy articles are included in the review. Helenalin is found to cure chronic conditions like rheumatoid arthritis, ulcers and malignancies like stomach, colon, breast, larynx, lung and skin cancers via multiple mechanisms. These diseases do not proceed via a unilateral pathway. So, it can be a useful molecule to treat numerous diseases. Conclusion: This review article will help us to systemically analyze the wealth of information concerning the medicinal properties of helenalin and to recognize the gaps which have vetoed its pervasive application in the medical community.

The Use of Methotrexate in Rheumatoid Arthritis

1985 ◽  
Vol 19 (5) ◽  
pp. 349-358 ◽  
Author(s):  
Peter W. Letendre ◽  
Douglas J. DeJong ◽  
Donald R. Miller
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trials ◽  
Folic Acid ◽  
Side Effects ◽  
Adverse Effects ◽  
Systemic Administration ◽  
Refractory Disease ◽  
Controlled Clinical Trials ◽  
Folic Acid Antagonist ◽  
Acid Antagonist

The use of methotrexate in rheumatoid arthritis is reviewed. Methotrexate, a folic acid antagonist, is sometimes employed in an attempt to symptomatically control patients whose disease does not respond adequately to conventional therapies. Systemic administration of 7.5–15 mg/wk in a “pulse” fashion appears to be effective without precipitating severe adverse effects. However, concern over potentially serious side effects and a lack of well-controlled clinical trials have limited its use to severe, refractory disease. Further studies are needed before its role in rheumatoid arthritis can justifiably be expanded.

Nonsteroidal anti-inflammatory drug use does not affect short-term endoscopic and histologic outcomes afterHelicobacter pylorieradication in patients with rheumatoid arthritis

2007 ◽  
Vol 17 (3) ◽  
pp. 228-234 ◽  
Author(s):  
Eiichi Tanaka ◽  
Shigeo Kamitsuji ◽  
Eisuke Inoue ◽  
Toru Yamada ◽  
Ayako Nakajima ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Use ◽  
Short Term ◽  
Inflammatory Drug ◽  
Anti Inflammatory

A GASTROSCOPIC STUDY OF THE PREDICTIVE VALUE OF RISK FACTORS FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUG-ASSOCIATED ULCER DISEASE IN RHEUMATOID ARTHRITIS PATIENTS

Rheumatology ◽  
1994 ◽  
Vol 33 (5) ◽  
pp. 449-454 ◽  
Author(s):  
M. JANSSEN ◽  
B. A. C. DIJKMANS ◽  
C. B. H. W. LAMERS ◽  
A. H. ZWINDERMAN ◽  
J. P. VANDENBROUCKE
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Predictive Value ◽  
Inflammatory Drug ◽  
Ulcer Disease ◽  
Anti Inflammatory

scholarly journals Prediction of sustained biologic and targeted synthetic DMARD free remission in rheumatoid arthritis patients

2021 ◽  
Author(s):  
Theresa Burkard ◽  
Ross D Williams ◽  
Enriqueta Vallejo-Yagüe ◽  
Thomas Hügle ◽  
Axel Finckh ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Use ◽  
External Validation ◽  
Penalized Regression ◽  
Validation Dataset ◽  
Sustained Remission ◽  
Forward Selection ◽  
Good Efficiency ◽  
Inflammatory Drug ◽  
Anti Inflammatory

Abstract Objectives To develop a prediction model of sustained remission following biologic or targeted synthetic disease modifying antirheumatic drug (b/tsDMARD) stop in rheumatoid arthritis (RA). Methods We conducted an explorative cohort study among b/tsDMARD RA treatment episodes courses stopped due to remission in the Swiss Clinical Quality Management registry (SCQM) [2008–2019]. The outcome was sustained b/tsDMARD free remission of ≥ 12 months. We applied logistic regression model selection algorithms using stepwise, forward, backward selection, and penalized regression to identify patient characteristics predictive of sustained b/tsDMARD free remission. We compared c-statistics corrected for optimism between models. The three models with highest c-statistics were validated in new SCQM data until 2020 (validation dataset). Results We identified 302 eligible episodes of which 177 episodes (59%) achieved sustained b/tsDMARD free remission. Two backward and one forward selection model with eight, four, and seven variables, respectively, obtained highest c-statistics corrected for optimism of c = 0·72, c = 0·70, and c = 0·69, respectively. In the validation dataset (47 eligible episodes), the models performed with c = 0·99, c = 0·80, and c = 0·74, respectively, and excellent calibration. The best model included the following 8 variables (measured at b/tsDMARD stop): RA duration, b/tsDMARD duration, other pain/anti-inflammatory drug use, quality of life (EuroQol), DAS28-erythrocyte sedimentation rate score, health assessment questionnaire (HAQ) score, education, and interactions of RA duration and other pain/anti-inflammatory drug use, and of b/tsDMARD duration and HAQ score. Conclusion Our results suggest that models with up to eight unique variables may predict sustained b/tsDMARD free remission with good efficiency. External validation is warranted.

Sign in / Sign up

Export Citation Format

Share Document